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The concept of using tamoxifen to prevent breast cancer
is a good one. Experimental evidence [1] shows that this
drug prevents the development of experimental oestrogen-
dependent mammary tumours, and there is now clear evi-
dence [2] that it will reduce the incidence of contralateral
breast cancers by about 50%.
In 1986 we started a feasibility trial at the Royal Marsden
Hospital to determine whether it is possible to use such
an intervention in healthy women to prevent breast cancer.
At that time, only women at high risk because of a strong
family history could be considered eligible for such a trial.
By 1989 we had clearly shown that tamoxifen had very
selective anti-oestrogenic activity that conferred safety
factors for cardiovascular disease and bone [3], which jus-
tified the start of multicentre trials. In 1992 the National
Surgical Adjuvant Breast and Bowel Project (NSABP)
started such at trial (P-1) in the USA, and a similar trial
was started in Milan that was followed in 1993 by the UK
International Breast Cancer Intervention Study (IBIS).
Following the publication of the results of an interim analy-
sis of the NSABP P-1 trial [4], which showed a 49%
reduction in the incidence of breast cancer, there has
been much debate about the possible use of tamoxifen in
healthy women. The debate has not been about the valid-
ity of these results, but rather about the magnitude of the
overall clinical benefit from this observed reduction. This is
especially important because the long-term effect on inci-
dence and the overall health benefit from using tamoxifen
in healthy women is not known at present. Furthermore,
there is the possibility that significant groups of women at
risk may not gain benefit and may even be harmed by
tamoxifen.
There is no doubt that the result of the interim analysis of
the P-1 trial showed a clear-cut, very significant
(P < 0.00001) 49% reduction in the incidence of breast
cancer over the 4 years of follow up in the 6681 women
who were randomised to tamoxifen 20 mg/day compared
with the 6707 women who were randomized to placebo
[4]. The inclusion criteria for the P-1 trial was based on the
model of risk of Gail et al [5], indicating a 5-year absolute
risk of 1.66% or greater, or a previous history of lobular
carcinoma in situ (LCIS). All categories of risk within the
Gail model based on age, previous benign histology and
family history of breast cancer appeared to gain benefit.
Participants who had had previous benign histology with
atypical hyperplasia appeared to gain most benefit (rela-
tive risk 0.14, LCIS relative risk 0.44). This means that the
remaining group of participants defined by the Gail model
(without atypical histology or LCIS) had a reduction in
early incidence of breast cancer of only about 40%.
Concerns about the application of the benefits of tamox-
ifen from the P-1 results to all healthy women arose from
the publication of the interim results of two smaller tamox-
ifen breast cancer chemoprevention trials (the Royal
Marsden trial and the Italian trial) in healthy women [6,7].
Both of these trials showed no effect of tamoxifen on
breast cancer incidence. Although the statistical powers
of these trials were substantially less than that of the P-1
trial [4], it is unlikely that lack of power, low compliance or
use of hormone replacement therapy contributed signifi-
cantly to these negative results. This raised the possibility
that the different population characteristics of the partici-
pants in the three trials could contribute to these different
results [8]. In the Italian trial about 40% of the participants
had had oophorectomy, which could have compromisedhttp://breast-cancer-research.com/content/2/1/010
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any subsequent tamoxifen effect. In the Royal Marsden
trial participants were more likely to have inherited a high-
risk breast cancer gene that could predispose to tamox-
ifen resistance. These negative results could therefore
indicate that there may be subgroups of healthy women
who may be resistant to tamoxifen chemoprevention.
The encouraging results from the interim analysis of the P-1
trial [4] required that the trial should be stopped and
unblinded before completion of the planned follow up. This
meant that further follow up of P-1 to establish the longer
term effect of tamoxifen on breast cancer incidence and mor-
tality would not be possible. This is unfortunate, because the
effects of tamoxifen may vary at different stages in breast
cancer tumourigenesis. In the early development of breast
cancer, tamoxifen could permanently disrupt the carcino-
genic process and give rise to long-term prevention. Later in
the natural history of the disease, before the clinical appear-
ance of the cancer, tamoxifen may only treat occult but
established cancers. This would reduce the early incidence
of breast cancer, but may give rise to only temporary remis-
sions. The later that tamoxifen is given before the presenta-
tion of clinical cancer, the less likely it is that it will be
permanently effective. At this time it is not possible to extrap-
olate from the early incidence data from P-1 to the probable
long-term effects of tamoxifen on breast cancer incidence in
healthy women. This will only become possible from the
long-term continued follow up of European trials such as
IBIS, which has now enrolled over 7000 healthy women.
Another major concern about the P-1 results [4] relates to
the assessment of overall clinical benefit from the reported
reduction in early incidence of breast cancer. Of the
13388 women in the P-1 trial there were 86 fewer
patients who developed invasive breast cancers on tamox-
ifen compared with placebo, together with 26 fewer
patients who developed ‘osteoporotic’ fractures. Rather
surprisingly, no reduction was observed in the number of
myocardial infarctions. As anticipated there were 21 extra
endometrial cancers, 14 extra strokes, 12 extra pulmonary
emboli, 13 extra deep vein thromboses, and 67 extra
patients with cataracts.
It is clearly difficult to balance the relative gain and loss
from these beneficial and harmful effects of tamoxifen at
this time, and even more difficult to predict how these
rates of clinical benefit and harm may change with longer
follow up. This is particularly important because there is no
evidence of a reduction in breast cancer mortality for
women on tamoxifen. The 86 fewer breast cancers were
all oestrogen-receptor positive, were mostly less than 2
cm in diameter, and were mostly axillary node negative,
indicating an 80–90% curability. Therefore, the question
of whether it would have been better to treat 86 extra
patients with good prognosis breast cancer rather than
6466 healthy women remains unanswered.
Nonetheless, the P-1 results [4] are very encouraging,
indicating that there is a real possibility that tamoxifen
will prevent the long-term incidence of breast cancer,
and that this will give rise to long-term overall clinical
benefit that will justify its use in large numbers of healthy
women. Clearly, the lack of data on breast cancer mortal-
ity, with no evidence of overall treatment benefit, and no
adequate explanation for the negative Royal Marsden
and Italian trials leave many questions unanswered. With
the closure of the P-1 trial these questions can only be
answered by the continued accrual and follow up of the
European trials.
Because of the detrimental side effects of tamoxifen, par-
ticularly on the uterus, the search has been on for other
agents that have a spectrum of oestrogenic and anti-
oestrogenic activity on various tissues of the body that
may be more attractive overall. One such agent is ralox-
ifene, which has been shown experimentally to be anti-
oestrogenic on breast and uterus, but oestrogenic on
bone and lipids [1,9,10]. A large double-blind, placebo-
controlled clinical trial of raloxifene involving 12512
healthy postmenopausal women at increased risk of
osteoporosis because of a reduced bone mineral density
[Multiple Outcomes of Raloxifene Evaluation (MORE)
trial] [11] has clearly shown that raloxifene will reduce
the risk of osteoporotic fractures. Participants in this trial
had annual mammography in order to evaluate a sec-
ondary end point of breast cancer incidence. An interim
analysis of these data [12] clearly shows a substantial
reduction in the incidence of breast cancer, with no evi-
dence of an increase in the incidence of endometrial
cancer. The NSABP has now started a new trial [the
Study of Tamoxifen and Raloxifene (STAR)], which aims
to recruit 22000 healthy women to compare directly the
effects of raloxifene versus tamoxifen on the incidence of
breast cancer and toxicity.
So where do we go from here? I believe we should con-
tinue the follow up of the Royal Marsden trial and continue
accrual and follow up of the IBIS trial. It may be possible
to have an overview meta-analysis of all trials in 2005, in
order to identify the long-term effects of tamoxifen on inci-
dence and mortality, and which subgroups of healthy
women at risk gain benefit. Continued follow up of the
raloxifene MORE trial will be very important, as will accrual
and follow up of the STAR trial directly comparing tamox-
ifen with raloxifene. Finally, it will be important to continue
to pilot new initiatives, particularly new selective estrogen
receptor modulators, as they become available. In low-risk
healthy women we would like to evaluate dietary con-
stituents such as isoflavonoids. In higher risk women, the
role of endocrine agents that have no agonist effects on
the breast, such as luteinizing hormone-releasing hormone
agonists, aromatase inhibitors and pure anti-oestrogens,
should be investigated as potential interventions.Breast Cancer Research    Vol 2 No 1 Powles
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With the encouraging results of the P-1 trial [4], the
endocrine chemoprevention of breast cancer is a reality.
We must never forget, however, that this involves treat-
ment of very large numbers of healthy women in order to
reduce the incidence of a few cancers. The level of
acceptable toxicity is therefore very much lower than it is
for treatment trials. It is therefore imperative that the out-
comes for these trials should include factors other than
early incidence, in order to be able to show long-term
treatment benefit in healthy women.
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